Velusetrag ( DrugBank: Velusetrag )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 99 | Chronic intestinal pseudo-obstruction | 1 |
99. Chronic intestinal pseudo-obstruction
Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-000854-24-IT (EUCTR) | 17/09/2021 | 18/10/2021 | Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO) | Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A | Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary. MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Velusetrag Product Code: [TD-5108 hydrochloride] INN or Proposed INN: Velusetrag Other descriptive name: THRX-199687 hydrochloride | ALFASIGMA S.P.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 2 | Spain;Belgium;Italy |